Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of
chronic myeloid leukemia (CML) with interferon-α (IFN-α), but CCgRs are rare. The mean …

The treatment recommendations for chronic myelogenous leukemia (CML) are evolving
rapidly. In the past year, pegylated interferon and STI571 (Gleevec, imatinib mesylate), a Bcr …

The fusion transcript AML1/ETO corresponding to translocation t (8; 21)(q22; q22) can be
found in approximately 7–12% of childhood de novo AML. Despite the favorable prognosis …

Interferon-alfa (IFNα) became the first-line agent for the treatment of chronic myeloid
leukemia (CML) because it prolongs survival significantly compared to conventional …

A high percentage of patients with leukemia, lymphoma, and solid tumors achieve a
complete clinical remission after initial treatment, but the majority of these patients will finally …

Dr. Silver: Chronic myeloid leukemia remains an enigma in origin and a source of frustration
in treatment, for no real progress has bean made in altering its natural history. Nevertheless …

A variety of molecular-based targets are potentially amenable to analysis for the evaluation
of minimal residual disease (MRD) following attempts at curative therapies in hematological …

Background: Contradictory results have been reported in terms of detecting bcr/abl
transcripts in patients with essential thrombocythemia. The aim of this study was to …

Most CML patients will receive imatinib as first-line therapy. For these patients serial
analysis of BCR-ABL blood levels by real time quantitative PCR (RQ-PCR) provides the …

Kind-Philipp Symposion in Honor to the Trustor Dr.-Ing. Walter Reiners and Kind-Philipp
Award 2008 handlung und Prognose der an Leuk ä mie und Krebs erkrankten Kinder [26] …